INCYTE CORP innovation strategy

Patent filings in countries

#	Country	Total Patents
#1	United States	619
#2	WIPO (World Intellectual Property Organization)	300
#3	EPO (European Patent Office)	140
#4	Australia	139
#5	Canada	121
#6	Taiwan	121
#7	China	111
#8	Singapore	104
#9	Argentina	93
#10	Republic of Korea	87
#11	Brazil	86
#12	Israel	78
#13	Mexico	73
#14	Costa Rica	70
#15	Chile	63
#16	Ecuador	54
#17	Colombia	46
#18	Peru	45
#19	Philippines	43
#20	Japan	34
#21	New Zealand	31
#22	Hong Kong	28
#23	South Africa	27
#24	Ukraine	26
#25	EAPO (Eurasian Patent Organization)	24
#26	Serbia	17
#27	Norway	15
#28	Morocco	13
#29	Hungary	12
#30	Georgia	9
#31	Tunisia	9
#32	Montenegro	8
#33	Jordan	7
#34	African Regional Industrial Property Organization	5
#35	Cuba	5
#36	Malaysia	5
#37	Dominican Republic	4
#38	Iceland	3
#39	Sweden	3
#40	Nicaragua	2
#41	Poland	2
#42	El Salvador	2
#43	Uruguay	2
#44	Honduras	1
#45	India	1
#46	Netherlands	1
#47	African Intellectual Property Organization	1
#48	Panama	1
#49	Slovenia	1

#	Technology
#1	Therapeutic chemical compounds
#2	Heterocyclic compounds
#3	Medical preparations
#4	Organic chemistry methods
#5	Peptides
#6	Analysing materials
#7	Microorganisms
#8	Special acyclic compounds
#9	Measuring microorganism processes
#10	Unspecified technologies

Publication	Filing date	Title
US2021113566A1	2020-10-16	Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
WO2021076728A1	2020-10-15	Bicyclic heterocycles as fgfr inhibitors
WO2021076602A1	2020-10-14	Bicyclic heterocycles as fgfr inhibitors
WO2021072232A1	2020-10-09	Bicyclic amines as cdk2 inhibitors
US2021123931A1	2020-10-08	Biomarkers for graft-versus-host disease
WO2021072116A1	2020-10-08	Biomarkers for graft-versus-host disease
US2021094935A1	2020-09-30	Bicyclic heterocycles as fgfr inhibitors
US2021094976A1	2020-09-29	Pyrido[3,2-d]pyrimidine compounds as immunomodulators
US2021030672A1	2020-09-16	Topical treatment of vitiligo by a jak inhibitor
US2021069195A1	2020-09-04	Ruxolitinib formulation for reduction of itch in atopic dermatitis
WO2021041360A1	2020-08-25	Triazolopyrimidines as a2a / a2b inhibitors
US2021047294A1	2020-08-13	Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2021030162A1	2020-08-07	Salts of a pd-1/pd-l1 inhibitor
US2021040071A1	2020-08-05	Solid forms of an hpk1 inhibitor
WO2021022172A1	2020-07-31	A dosing regimen for an ido inhibitor
US2021009582A1	2020-07-08	Bicyclic heterocycles as fgfr inhibitors
WO2020252012A1	2020-06-10	Topical treatment of vitiligo by a jak inhibitor
US2020347066A1	2020-04-30	Tricyclic amine compounds as cdk2 inhibitors
US2020347067A1	2020-04-30	Tricyclic amine compounds as cdk2 inhibitors
WO2020223235A1	2020-04-28	Mini-tablet dosage forms of ponatinib